RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
ProMIS Neurosciences Stock

ProMIS Neurosciences EBIT 2024

ProMIS Neurosciences EBIT

-17.07 M CAD

Ticker

PMN.TO

ISIN

CA74346M1095

WKN

A14WN0

In 2024, ProMIS Neurosciences's EBIT was -17.07 M CAD, a -21.03% increase from the -21.61 M CAD EBIT recorded in the previous year.

The ProMIS Neurosciences EBIT history

YEAREBIT (undefined CAD)
2029e-
2028e29.46
2027e-8.23
2026e-17.13
2025e-22.62
2024e-17.07
2023e-21.61
2022-23.38
2021-8.29
2020-5.66
2019-7.4
2018-10.17
2017-6.01
2016-3.44
2015-1.99
2014-2.14
2013-2.25
2012-2.23
2011-2.56
2010-3.25
2009-4.86
2008-5.15
2007-7.19
2006-4.23
2005-1.49
2004-0.16

ProMIS Neurosciences Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into ProMIS Neurosciences, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by ProMIS Neurosciences from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects ProMIS Neurosciences’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of ProMIS Neurosciences. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into ProMIS Neurosciences’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing ProMIS Neurosciences’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on ProMIS Neurosciences’s growth potential.

ProMIS Neurosciences Revenue, EBIT and net profit per share

DateProMIS Neurosciences RevenueProMIS Neurosciences EBITProMIS Neurosciences Net Income
2029e148.44 M undefined0 undefined0 undefined
2028e36.34 M undefined29.46 M undefined0 undefined
2027e0 undefined-8.23 M undefined-10.17 M undefined
2026e0 undefined-17.13 M undefined-20.63 M undefined
2025e0 undefined-22.62 M undefined-17.51 M undefined
2024e0 undefined-17.07 M undefined-13.23 M undefined
2023e0 undefined-21.61 M undefined-16.72 M undefined
20220 undefined-23.38 M undefined-18.06 M undefined
20210 undefined-8.29 M undefined-9.79 M undefined
20200 undefined-5.66 M undefined-5.66 M undefined
20190 undefined-7.4 M undefined-7.4 M undefined
20180 undefined-10.17 M undefined-10.17 M undefined
201710,000 undefined-6.01 M undefined-6.02 M undefined
20160 undefined-3.44 M undefined-3.45 M undefined
201520,000 undefined-1.99 M undefined-2.12 M undefined
2014260,000 undefined-2.14 M undefined-2.14 M undefined
2013150,000 undefined-2.25 M undefined-2.25 M undefined
201250,000 undefined-2.23 M undefined-2.23 M undefined
201190,000 undefined-2.56 M undefined-2.54 M undefined
20101.15 M undefined-3.25 M undefined-3.2 M undefined
2009180,000 undefined-4.86 M undefined-4.86 M undefined
2008240,000 undefined-5.15 M undefined-5.15 M undefined
2007480,000 undefined-7.19 M undefined-7.19 M undefined
2006250,000 undefined-4.23 M undefined-4.23 M undefined
200540,000 undefined-1.49 M undefined-1.97 M undefined
20040 undefined-160,000 undefined-160,000 undefined

ProMIS Neurosciences stock margins

The ProMIS Neurosciences margin analysis displays the gross margin, EBIT margin, as well as the profit margin of ProMIS Neurosciences. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for ProMIS Neurosciences.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the ProMIS Neurosciences's sales revenue. A higher gross margin percentage indicates that the ProMIS Neurosciences retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the ProMIS Neurosciences's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the ProMIS Neurosciences's total revenue generated. When comparing the revenue margin year over year, investors can gauge the ProMIS Neurosciences's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the ProMIS Neurosciences. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the ProMIS Neurosciences's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

ProMIS Neurosciences Margin History

ProMIS Neurosciences Gross marginProMIS Neurosciences Profit marginProMIS Neurosciences EBIT marginProMIS Neurosciences Profit margin
2029e0 %0 %0 %
2028e0 %81.07 %0 %
2027e0 %0 %0 %
2026e0 %0 %0 %
2025e0 %0 %0 %
2024e0 %0 %0 %
2023e0 %0 %0 %
20220 %0 %0 %
20210 %0 %0 %
20200 %0 %0 %
20190 %0 %0 %
20180 %0 %0 %
20170 %-60,100.01 %-60,200 %
20160 %0 %0 %
20150 %-9,950 %-10,600 %
20140 %-823.08 %-823.08 %
20130 %-1,500 %-1,500 %
20120 %-4,460 %-4,460 %
20110 %-2,844.44 %-2,822.22 %
20100 %-282.61 %-278.26 %
20090 %-2,700 %-2,700 %
20080 %-2,145.83 %-2,145.83 %
20070 %-1,497.92 %-1,497.92 %
20060 %-1,692 %-1,692 %
20050 %-3,725 %-4,925 %
20040 %0 %0 %

ProMIS Neurosciences Aktienanalyse

What does ProMIS Neurosciences do?

ProMIS Neurosciences Inc is a biopharmaceutical company based in Canada that specializes in the discovery and development of novel therapeutics for neurodegenerative diseases such as Alzheimer's, Parkinson's, and ALS. The company was founded in 2004 and has been listed on the Toronto Stock Exchange since 2015. The goal of ProMIS is to develop highly specific therapeutics that specifically target the cellular causes of neurodegenerative diseases and can therefore stop or even reverse the progression of the disease. The company utilizes its proprietary platform technology to identify the unique epitopes on the pathological proteins that are specific to neurodegenerative diseases. ProMIS' business model is based on partnerships with large pharmaceutical companies that are searching for new therapeutics for neurodegenerative diseases. ProMIS works closely with these partners to develop customized therapeutics tailored to each partner's specific needs. The company licenses its technology and products to its partners and receives license and milestone payments when certain development or sales goals are achieved. ProMIS has different divisions to focus on various neurodegenerative diseases, with a focus on Alzheimer's, Parkinson's, and ALS. ProMIS has a comprehensive research and development infrastructure that focuses on the identification, characterization, and optimization of therapeutic antibodies and biomarkers. In terms of products, ProMIS has developed various antibodies that specifically target pathological proteins such as Aß and Tau in Alzheimer's and alpha-synuclein in Parkinson's. These antibodies can selectively recognize and bind to these pathological proteins, allowing them to be broken down and removed from the body. ProMIS works closely with its partners to test these antibodies in clinical trials and eventually bring them to market. In addition to its antibody products, ProMIS has also developed neuromethods that allow researchers to characterize and quantify the functions of proteins in brain cells and in vivo. These methods can be used to test and optimize the effects of antibodies and other therapeutics, making them an important part of ProMIS' development infrastructure. Overall, ProMIS Neurosciences Inc is an innovative biopharmaceutical company that focuses on the development of highly specific therapeutics for neurodegenerative diseases. The company has a comprehensive infrastructure and technology platform that allows it to develop customized products for its partners. With its antibodies and neuromethods, ProMIS has the potential to make a breakthrough in the treatment of neurodegenerative diseases and improve the lives of millions of patients. ProMIS Neurosciences ist eines der beliebtesten Unternehmen auf Eulerpool.com.

EBIT Details

Analyzing ProMIS Neurosciences's EBIT

ProMIS Neurosciences's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of ProMIS Neurosciences's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

ProMIS Neurosciences's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in ProMIS Neurosciences’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about ProMIS Neurosciences stock

How much did ProMIS Neurosciences achieve in EBIT for the current year?

In the current year, ProMIS Neurosciences has achieved an EBIT of -17.07 M CAD.

What is EBIT?

EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company ProMIS Neurosciences.

How has the EBIT of ProMIS Neurosciences developed in recent years?

The EBIT of ProMIS Neurosciences has increased by -21.028% decreased compared to the previous year.

What does EBIT mean for investors?

EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.

Why is EBIT an important indicator for investors?

Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.

Why do EBIT values fluctuate?

EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.

What role does tax burden play in EBIT?

Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.

How is EBIT presented in the balance sheet of the company ProMIS Neurosciences?

The EBIT of ProMIS Neurosciences is listed in the income statement.

Can EBIT be used as a single indicator for evaluating a company?

EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.

Why is EBIT not equal to net profit?

The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.

How much dividend does ProMIS Neurosciences pay?

Over the past 12 months, ProMIS Neurosciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, ProMIS Neurosciences is expected to pay a dividend of 0 CAD.

What is the dividend yield of ProMIS Neurosciences?

The current dividend yield of ProMIS Neurosciences is .

When does ProMIS Neurosciences pay dividends?

ProMIS Neurosciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of ProMIS Neurosciences?

ProMIS Neurosciences paid dividends every year for the past 0 years.

What is the dividend of ProMIS Neurosciences?

For the upcoming 12 months, dividends amounting to 0 CAD are expected. This corresponds to a dividend yield of 0 %.

In which sector is ProMIS Neurosciences located?

ProMIS Neurosciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von ProMIS Neurosciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of ProMIS Neurosciences from 9/17/2024 amounting to 0 CAD, you needed to have the stock in your portfolio before the ex-date on 9/17/2024.

When did ProMIS Neurosciences pay the last dividend?

The last dividend was paid out on 9/17/2024.

What was the dividend of ProMIS Neurosciences in the year 2023?

In the year 2023, ProMIS Neurosciences distributed 0 CAD as dividends.

In which currency does ProMIS Neurosciences pay out the dividend?

The dividends of ProMIS Neurosciences are distributed in CAD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The ProMIS Neurosciences stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von ProMIS Neurosciences

Our stock analysis for ProMIS Neurosciences Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of ProMIS Neurosciences Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.